onr:"swepub:oai:prod.swepub.kib.ki.se:148604800"
Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:148604800" > Biologicals in chil...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04328naa a2200817 4500 | |
| 001 | oai:prod.swepub.kib.ki.se:148604800 | |
| 003 | SwePub | |
| 008 | 240701s2021 | |||||||||||000 ||eng| | |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1486048002 URI |
| 024 | 7 | a https://doi.org/10.1183/23120541.00143-20212 DOI |
| 040 | a (SwePub)ki | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Santos-Valente, E4 aut |
| 245 | 1 0 | a Biologicals in childhood severe asthma: the European PERMEABLE survey on the status quo |
| 264 | c 2021-06-03 | |
| 264 | 1 | b European Respiratory Society (ERS),c 2021 |
| 520 | a Severe asthma is a rare disease in children, for which three biologicals, anti-immunoglobulin E, anti-interleukin-5 and anti-IL4RA antibodies, are available in European countries. While global guidelines exist on who should receive biologicals, knowledge is lacking on how those guidelines are implemented in real life and which unmet needs exist in the field. In this survey, we aimed to investigate the status quo and identify open questions in biological therapy of childhood asthma across Europe.MethodsStructured interviews regarding experience with biologicals, regulations on access to the different treatment options, drug selection, therapy success and discontinuation of therapy were performed. Content analysis was used to analyse data.ResultsWe interviewed 37 experts from 25 European countries and Turkey and found a considerable range in the number of children treated with biologicals per centre. All participating countries provide public access to at least one biological. Most countries allow different medical disciplines to prescribe biologicals to children with asthma, and only a few restrict therapy to specialised centres. We observed significant variation in the time point at which treatment success is assessed, in therapy duration and in the success rate of discontinuation. Most participating centres intend to apply a personalised medicine approach in the future to match patients a priori to available biologicals.ConclusionSubstantial differences exist in the management of childhood severe asthma across Europe, and the need for further studies on biomarkers supporting selection of biologicals, on criteria to assess therapy response and on how/when to end therapy in stable patients is evident. | |
| 700 | 1 | a Buntrock-Dopke, H4 aut |
| 700 | 1 | a Abou Taam, R4 aut |
| 700 | 1 | a Arasi, S4 aut |
| 700 | 1 | a Bakirtas, A4 aut |
| 700 | 1 | a Blasco, JL4 aut |
| 700 | 1 | a Bonnelykke, K4 aut |
| 700 | 1 | a Craiu, M4 aut |
| 700 | 1 | a Cutrera, R4 aut |
| 700 | 1 | a Deschildre, A4 aut |
| 700 | 1 | a Elnazir, B4 aut |
| 700 | 1 | a Fleming, L4 aut |
| 700 | 1 | a Frey, U4 aut |
| 700 | 1 | a Gappa, M4 aut |
| 700 | 1 | a Garcia, AN4 aut |
| 700 | 1 | a Hansen, KS4 aut |
| 700 | 1 | a Hanssens, L4 aut |
| 700 | 1 | a Jahnz-Rozyk, K4 aut |
| 700 | 1 | a Jesenak, M4 aut |
| 700 | 1 | a Kerzel, S4 aut |
| 700 | 1 | a Kopp, MV4 aut |
| 700 | 1 | a Koppelman, GH4 aut |
| 700 | 1 | a Krivec, U4 aut |
| 700 | 1 | a MacLeod, KA4 aut |
| 700 | 1 | a Makela, M4 aut |
| 700 | 1 | a Melen, Eu Karolinska Institutet4 aut |
| 700 | 1 | a Mezei, G4 aut |
| 700 | 1 | a Moeller, A4 aut |
| 700 | 1 | a Moreira, A4 aut |
| 700 | 1 | a Pohunek, P4 aut |
| 700 | 1 | a Minic, P4 aut |
| 700 | 1 | a Rutjes, NWP4 aut |
| 700 | 1 | a Sammut, P4 aut |
| 700 | 1 | a Schwerk, N4 aut |
| 700 | 1 | a Szepfalusi, Z4 aut |
| 700 | 1 | a Turkalj, M4 aut |
| 700 | 1 | a Tzotcheva, I4 aut |
| 700 | 1 | a Ulmeanu, A4 aut |
| 700 | 1 | a Verhulst, S4 aut |
| 700 | 1 | a Xepapadaki, P4 aut |
| 700 | 1 | a Niggel, J4 aut |
| 700 | 1 | a Vijverberg, S4 aut |
| 700 | 1 | a Maitland-van der Zee, AH4 aut |
| 700 | 1 | a Potocnik, U4 aut |
| 700 | 1 | a Reinartz, SM4 aut |
| 700 | 1 | a van Drunen, CM4 aut |
| 700 | 1 | a Kabesch, M4 aut |
| 710 | 2 | a Karolinska Institutet4 org |
| 773 | 0 | t ERJ open researchd : European Respiratory Society (ERS)g 7:3q 7:3x 2312-0541 |
| 856 | 4 | u https://openres.ersjournals.com/content/erjor/7/3/00143-2021.full.pdf |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:148604800 |
| 856 | 4 8 | u https://doi.org/10.1183/23120541.00143-2021 |
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Santos-Valente, ...
- Buntrock-Dopke, ...
- Abou Taam, R
- Arasi, S
- Bakirtas, A
- Blasco, JL
- visa fler...
- Bonnelykke, K
- Craiu, M
- Cutrera, R
- Deschildre, A
- Elnazir, B
- Fleming, L
- Frey, U
- Gappa, M
- Garcia, AN
- Hansen, KS
- Hanssens, L
- Jahnz-Rozyk, K
- Jesenak, M
- Kerzel, S
- Kopp, MV
- Koppelman, GH
- Krivec, U
- MacLeod, KA
- Makela, M
- Melen, E
- Mezei, G
- Moeller, A
- Moreira, A
- Pohunek, P
- Minic, P
- Rutjes, NWP
- Sammut, P
- Schwerk, N
- Szepfalusi, Z
- Turkalj, M
- Tzotcheva, I
- Ulmeanu, A
- Verhulst, S
- Xepapadaki, P
- Niggel, J
- Vijverberg, S
- Maitland-van der ...
- Potocnik, U
- Reinartz, SM
- van Drunen, CM
- Kabesch, M
- visa färre...
- Artiklar i publikationen
- ERJ open researc ...
- Av lärosätet
- Karolinska Institutet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
